Ascendis Pharma A/S
Open
$231.89
Prev. Close
$231.83
High
$232.22
Low
$230.90
Market Snapshot
$14.19B
24.7
-7.09
$388.36M
Ascendis Pharma A/S is a DK-based company operating in Biotechnology industry. Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The firm scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.
Ascendis Pharma A/S is a DK-based company operating in Biotechnology industry. Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The firm scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.
Recently from Cashu
Ascendis Pharma's Yuviwel Approved: Pioneering Treatment for Children's Achondroplasia
Regulatory Success: Yuviwel Approval Marks a Major Milestone for Ascendis Pharma Ascendis Pharma A/S achieves a significant milestone with the recent approval of Yuviwel (navepegritide) by the U.S. Fo…
Ascendis Pharma's Yuviwel Approved by FDA, Advancing Pediatric Care for Achondroplasia
Ascendis Pharma Secures FDA Approval for Yuviwel, Advancing Pediatric Care for Achondroplasia Ascendis Pharma A/S achieves a significant milestone with the recent U.S. Food and Drug Administration (FD…
FDA Approves Yuviwel: A Game-Changer for Pediatric Achondroplasia Treatment by Ascendis Pharma
Yuviwel’s FDA Approval Marks a Milestone for Ascendis Pharma in Pediatric Treatment Ascendis Pharma A/S achieves a significant breakthrough with the recent approval from the U.S. Food and Drug Adminis…
Ascendis Pharma A/S Sees 10.27% Surge in Short Interest, Signaling Investor Concerns
Ascendis Pharma's Short Interest Surge: Implications for the Biotech Sector Ascendis Pharma A/S, a biotechnology company focused on innovative treatments, faces a significant rise in short interest, w…